CuriRx Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CuriRx's estimated annual revenue is currently $6.4M per year.(i)
  • CuriRx's estimated revenue per employee is $244,423

Employee Data

  • CuriRx has 26 Employees.(i)
  • CuriRx grew their employee count by -24% last year.

CuriRx's People

NameTitleEmail/Phone
1
Director BioprocessingReveal Email/Phone
2
Laboratory Operations ManagerReveal Email/Phone
3
Senior Manager: HR Operations, Culture & EngagementReveal Email/Phone
4
Staff ScientistReveal Email/Phone
5
ScientistReveal Email/Phone
6
Scientist IIReveal Email/Phone
7
Senior IT Support EngineerReveal Email/Phone
8
Accounting ControllerReveal Email/Phone
9
Research associateReveal Email/Phone
10
Formulation Development Co-OpReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M1-50%N/AN/A
#3
$5.1M3322%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M2-60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
N/A1110%N/AN/A
#10
$5.4M290%N/AN/A
Add Company

What Is CuriRx?

CuriRx, Inc. was founded in 2012 with the goal of creating new standards of care in therapeutic areas with high unmet medical needs. We do this by partnering with our clients to provide innovative development solutions for pharmaceutics, biopharmaceutics, vaccines, generics, and biosimilars. Our unique approach allows for: Strong collaboration Customized development plans Open discussion with strong consultative expertise Iterative ideation Maximized efficacy Guaranteed commitment and customer satisfaction We are a contract services company providing research and development for biotech and pharmaceutical products, and our scientists have more than 30 years’ experience in formulation development. We have worked with small molecules, peptides, proteins, vaccines, biosimilars, oligonucleotides, bacteria, cells, dextrans, combination products, conjugated products, antibodies, bispecific antibodies, and more. Our services include formulation development, lyophilization, cell culture and purification, analytical development, and more, and we have the capacity to produce non-GMP vials for animal studies and non-GMP stability support studies. Our past successful development projects include HUMIRA® and Synagis®. In addition to our R&D services, we are happy to consult with you in the areas of operational management, project management, GMP, cGMP, customized aseptic technique training, product development, and more.

keywords:N/A

N/A

Total Funding

26

Number of Employees

$6.4M

Revenue (est)

-24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.3M260%N/A
#2
$1.9M268%N/A
#3
$5.9M2613%N/A
#4
$2.9M2686%N/A
#5
$9.3M260%N/A